Search
Tigecycline
go.drugbank.com/drugs/DB00560ApprovedInvestigationalIt was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus. It was granted fast-track approval by the U.S. … Food and Drug Administration (FDA) on June 17, 2005.
Dabigatran etexilate
go.drugbank.com/drugs/DB06695ApprovedInvestigational[A177463] In contrast to warfarin, because its anticoagulant effects are predictable, lab monitoring is not necessary.[A177463] Dabigatran etexilate was approved by the FDA in 2010.[L6022] … Dabigatran etexilate is an oral prodrug that is hydrolyzed to the competitive and reversible direct thrombin inhibitor [dabigatran].
Technetium Tc-99m sestamibi
go.drugbank.com/drugs/DB09161ApprovedInvestigationalThe mechanism by which sestamibi localizes to these tissues has not been established. … Single photon emission computed tomography (SPECT) is then performed to detect the gamma ray emmitted by the decay of Technetium-99m to Technetium-99.
Dalbavancin
go.drugbank.com/drugs/DB06219ApprovedInvestigationalDalbavancin acts by interfering with bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of nascent cell wall peptidoglycan and preventing cross-linking [FDA Label, F2356, A4072 … Modifications from these older glycoprotein classes facilitated a similar mechanism of action for dalbavancin but with increased activity and once-weekly dosing [FDA Label, F2356, A4072, A4073].
Anthrax vaccine
go.drugbank.com/drugs/DB11003ApprovedInvestigational[L47561] There are currently 2 anthrax vaccines approved by the FDA: BioThrax in August 15, 2016 and CYFENDUS in July 20, 2023. … [L47526] It is considered one of the most likely agents to be used in a biological attack.
Magnesium salicylate
go.drugbank.com/drugs/DB01397ApprovedMagnesium salicylate is a non-steroidal anti-inflammatory drug (NSAID) used to treat mild to moderate pain. It is available in several over-the-counter (OTC) formulations. … Though the recommended doseage is 1160 mg every six hours, per package directions of the Doan's OTC brand (580 mg magnesium salicylate tetrahydrate, equivalent to 934.4 mg anhydrous magnesium salicylate
Categories: Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Analgesics, Non-NarcoticPegcetacoplan
go.drugbank.com/drugs/DB16694ApprovedInvestigational[A235000] Patients given eculizumab experienced less hemolysis caused by the membrane attack complex, but were still somewhat susceptible to hemolysis caused by C3b opsonization. … [L34095] In February 2023, pegcetacoplan for intravitreal use was approved by the FDA for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration.[L45354]
Drospirenone
go.drugbank.com/drugs/DB01395ApprovedInvestigationalSome studies have demonstrated a significantly increased risk and some demonstrating no risk of thromboembolic events. … In its statement, the FDA has mentioned that increased risk of venous thromboembolism with oral contraceptives such as drospirenone exists but remains lower than the risk of this condition during pregnancy
Mixtures: Lo-ZumandimineLevoketoconazole
go.drugbank.com/drugs/DB05667Approved[A244083, A29319, L39573] Levoketoconazole was approved by the FDA on December 30, 2021, and is currently marketed under the registered trademark RECORLEV by Xeris Pharmaceuticals, Inc.[L39563] … Cushing's syndrome (CS) is underpinned by chronic hypercortisolism leading to multisystem morbidity, including effects on the cardiovascular and endocrine systems, metabolic syndrome with accompanying
Sotrovimab
go.drugbank.com/drugs/DB16355ApprovedInvestigational[L34425, L34430, L34440] However, in April 2022, the FDA removed the EUA for sotrovimab due to the rising COVID-19 cases caused by the Omicron BA.2 sub-variant, where the drug is ineffective. … [L34440] Sotrovimab was initially been granted emergency use authorization (EUA) to treat mild-to-moderate COVID-19 on May 26, 2021, based on interim results from a clinical trial, where sotrovimab was